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Author's Abstract:  
An increasing number of serodiscordant couples are utilizing advanced reproductive technologies to address their reproductive 
needs. Recent literature has demonstrated that it is not only technically possible but also safe to utilize sperm-washing techniques 
to allow for the creation of embryos, thereby preventing both horizontal and vertical transmission of HIV. This article addresses 
the strengths and weakness of various reproductive techniques and discusses our experience at Columbia University (NY, USA), 
the location of the largest HIV-focused fertility program in the USA. 
Full Text:COPYRIGHT 2011 Future Medicine Ltd. 
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Globally, the number of individuals living with HIV in 2008 was estimated to be 33.4 million [101] . 
Approximately 1.1 million of these individuals reside in the USA [102] . While there is no cure for HIV, 
current treatment options -â articularly antiretroviral therapies (ARVs) -â allow many HIV-positive 
individuals to lead relatively normal lives, with greatly improved average life expectancy [1] . No 
differently from uninfected couples, serodiscordant couples often wish to have children. These 
serodiscordant couples have a variety of reproductive options, each with its own set of attendant risks 
and probabilities for success. Variations in clinical practice may dictate levels of expense and 
inconvenience associated with these techniques. However, the common goal of each method is 
reducing the risk of transmission of HIV to the mother and child by segregating the virus from the 
gametes used to create the embryo. 
Fertility desires & methods of conceiving  
While approximately 10 years ago, slightly less than a third of HIV-seropositive individuals in the USA 
desired children in the future, more recent reports indicate an overall increased interest in 
childbearing among HIV-seropositive individuals in the USA and around the world; this is 
commensurate with the improved treatment and health of those living with HIV [2,3] . Other than 
adopting a child or using frozen donor sperm insemination, male-positive serodiscordant couples who 
wish to conceive have elected to use timed intercourse (thus, reducing exposure to single acts of sex), 
or to use sperm that has been prepared for intrauterine insemination (IUI) or in vitro fertilization (IVF) 
with intracytoplasmic sperm injection (ICSI). Although timed intercourse may be the most cost-
effective means to achieve pregnancy, in serodiscordant couples, it also carries the greatest risk of 
HIV transmission. The estimated risk of seroconversion is approximately one in 1000-â2000 opposite-
sex sexual encounters, or less than 1% per sexual encounter [4,5] . More specifically, a recent meta-
analysis indicated a risk of 0.04-â0.38% per instance of sexual intercourse for female-to-male 
transmission and a 0.08-â0.30% risk per instance for male-to-female transmission [6] . As 
demonstrated, the risk of transmission from men to women is greater than that from women to men, 
and the risk of transmission most likely varies with levels of the HIV-positive partner’âs viral load [4,7] . 
Among 92 male-positive serodiscordant couples who conceived naturally through intercourse in one 
study, two women became HIV positive several months after becoming pregnant, and two other 
women became HIV positive after delivering their infants, with all four of these women indicating that 
they had not been using condoms regularly [8] . 
Processed semen that utilizes density-gradient centrifugation and ’âswim-up’â techniques is routinely 
performed by embryology/andrology laboratories prior to either IUI or IVF, and these have become 
popular options for serodiscordant couples seeking to safely become parents. Performing IUI with 
semen processing to allow male-positive serodiscordant couples to conceive was first reported in 1990 
by Semprini et al. [9] . After being diluted in medium, unfractionated semen samples are filtered to 
remove any fibers, microcalculus and mucinous debris. The remaining sperm sediment is then layered 
onto a linear gradient of solution and pelleted by centrifugation. The spermatozoa pellet, now 
separated from seminal plasma and seminal nonspermatozoa cells, is washed, overlaid with medium 
and incubated for 20-â30 min to allow motile spermatozoa to swim-up. The resulting supernatant 
containing motile spermatozoa is then collected [10-â13] . 
This semen-processing method, which effectively both segregates HIV from the cellular fraction 
(lymphocytes) and free virus from the sperm fraction, is termed ’âsperm washing’â, and is still 
commonly used today with continued success. 
The use of IUI or IVF with ICSI for treatment of HIV-positive patients differs between reproductive 
centers throughout the world. The lower cost and less-invasive approach of IUI is attractive to many 
couples, although this procedure has primarily been offered in Europe where use of IUI for infected 
men is not prohibited by law. A recent review of the experience at a reproductive center in the UK 
demonstrated that the choice between treatment options depends mostly on the patient’âs or 
couple’âs reproductive etiology [14] . In the USA, the Centers for Disease Control does not endorse the 
use of intrauterine insemination in serodiscordant couples, which has slowed the introduction of 
treating these couples owing to fear of civil, and possibly criminal, lawsuits among medical 
practitioners [15] . IVF with ICSI has been practiced instead, which avoids directly ’âinseminating’â with 
known viral risk and, over the past decade, has become the preferred methodology [16] . However, this 
method involves ovarian hyperstimulation, transvaginal oocyte removal under anesthesia, sperm 
washing, selection of the individual motile sperm and injection of the sperm directly into the oocyte for 
fertilization. Thus, this method has the advantage of reducing the risk of exposure to sperm carrying 
the virus but at the high cost of an IVF approach and the associated potential consequences of 
assisted reproductive technology (ART). 
Although IUI and IVF-âICSI demonstrated great success in terms of minimizing risk of seroconversion, 
IUI may be less effective compared with IVF in terms of pregnancy outcome results. For example, in a 
multicenter, retrospective analysis of 853 serodiscordant couples undergoing sperm washing with IUI, 
patients completed a total of 2840 cycles, with a resulting pregnancy rate per cycle of approximately 
15%, and a delivery rate per cycle of 11.5%; there were no female seroconversions at 6 months post-
treatment [17] . Another center reported a 19% pregnancy rate per IUI cycle, and a 13.5% delivery 
rate per cycle among 741 serodiscordant couples who completed a total of 2400 IUI cycles over a 4-
year period [18] . However, these pregnancy and delivery rates are less than half of the success rates 
reported elsewhere for IVF-âICSI for serodiscordant couples, which is typical when comparing success 
of IUI versus IVF per treatment cycle in the general population [19] . Advocates of the IUI approach 
argue that the lower multiple birth rate, lesser cost and relative noninvasiveness of the method justify 
the low-technical approach. Yet, many couples may prefer the immediacy of results and the ability to 
bank supernumerary embryos, afforded only through IVF. 
Sperm-washing technique common to IUI & IVF-âICSI  
As mentioned previously, the basic process of density-gradient centrifugation of semen followed by 
sperm swim-up has been in use for more than 20 years to treat serodiscordant couples interested in 
having a child [13] . The method has been well described in serodiscordant couples seeking to use IUI 
or IVF-âICSI, amassing over 3000 reported cycles without known seroconversion in the uninfected 
female [13,19] . In both techniques, male partners produce semen specimens by masturbation. 
When the specimen is being prepared for IUI, after the washing procedure, an aliquot of washed 
semen ([proportional to]â¼100 µÂµl) is commonly tested using PCR for detectable HIV RNA prior to 
the sample being used for treatment. In many programs, it is mandatory for couples to freeze a 
washed negative sample as a backup in case residual HIV is found in a post-wash sample that would 
otherwise necessitate cycle cancellation [20] . The resultant HIV-negative aliquot is injected using an 
insemination catheter into the uterine cavity. 
Sperm freezing further reduces the amount of viable sperm recovered for later insemination. Owing to 
their findings demonstrating the disadvantageous effect of frozen-âthawed sperm-washed specimens 
on total motile sperm counts, the Assisted Conception Unit at the Chelsea and Westminster Hospital in 
London (UK) has pursued the use of fresh semen samples as often as possible. Their center has 
recently adopted a new laboratory protocol that uses two instead of three wash cycles after density-
gradient centrifugation, and they only require the swim-up method for IUI cycles for male patients not 
receiving highly active antiretroviral therapy (HAART), with detectable viral loads or with semen 
samples with significant debris. The authors state that with the new laboratory protocol, they have 
noted a significantly higher proportion of total motile sperm available for IUI [14] . 
Another potential limitation with IUI relates to the fact that many men with HIV often have 
oligoasthenospermia, which complicates the recovery process. The etiology of these altered sperm 
characteristics has yet to be deduced, although there are a number of hypotheses. In an analysis of 
approximately 200 HIV-infected men in which 91% were undergoing HAART therapy, it was found that 
semen samples were commonly abnormal, with semen volumes, percentages of progressive mobile 
spermatozoa, total sperm counts and polymorphonuclear cell counts being decreased, while the pH 
values and spermatozoa multiple anomaly indices were increased [21] . The Assisted Conception Unit 
recently demonstrated that it is the semen analysis parameters that are more predictive of sperm-
washing/IUI success compared with the male patient’âs HIV parameters [22] . 
By comparing IUI with IVF-âICSI, one of the distinct advantages of IVF-âICSI is that only single, 
viable, motile and washed sperm are selected for use, as opposed to IUI, in which a cohort of millions 
of cells are selected. Furthermore, men with abnormal semen parameters, termed male-factor 
infertility, often have lower success rates with IUI therapy, and must ultimately resort to IVF-âICSI in 
order to improve fertilization. The lower per-cycle success rate usually results in additional IUI cycles 
and, thus, added exposure to the risk of infection as repetitive cycles accumulate. 
In our practice (the Center for Women’âs Reproductive Care at Columbia University, CO, USA), we 
elected to adopt an IVF approach when initiating a program for serodiscordant couples in 1998 [23] . 
Our experience over the last 10 years with 420 consecutive cycles of IVF with ICSI revealed that the 
clinical pregnancy rate per embryo transfer was 45%, while the ongoing/delivered pregnancy rate per 
embryo transfer was 37% [19] . This is comparable to the general IVF (nondonor oocyte) outcomes at 
our center. More specifically, the clinical pregnancy rate per embryo transfer was approximately 50% 
in 2009 for a similar age group (35-â40-year-old patients), and the live birth rate per embryo transfer 
was approximately 34% across the same age group for 2008. It is important to note that, in our 
practice, there has never been a female seroconversion following IVF-âICSI, nor has there been an 
HIV infection in any of the 170 delivered offspring [19] . Success with IVF in general -â and also for this 
subset -â is highly dependent upon the age of the woman, with younger patients (<35 years old) 
being much more likely to succeed than their older counterparts [23] . Examining the HIV-
serodiscordant patients, approximately 90% conceived successfully and delivered a child with three or 
fewer attempts, whereas women over 40 years were half as likely to experience pregnancy [24] . 
Experience at Columbia University  
At our center, HIV-seropositive men and their seronegative female partners can pursue having a 
family through HIV-negative-donor sperm insemination or through IVF-âICSI. IVF-âICSI has been 
offered to HIV-serodiscordant couples at Columbia University since 1997. In our first 10 years of 
experience, 258 male-positive HIV-serodiscordant couples presented for initial consultation, with 181 
proceeding with treatment [19] . Since our previous report, we have had an additional 50 male HIV-
serodiscordant couples present for consultation. To date, there have been 383 initiated fresh-egg 
donor and autologous IVF-âICSI cycles and 69 frozen-embryo transfer cycles at our center. A total of 
189 clinical pregnancies and 113 deliveries have resulted from 143 serodiscordant couples. 
When male-serodiscordant couples initially present to our center, they must complete a list of 
screening requirements before pursuing IVF-âICSI (Box 1). A female partner must be aware of her 
male partner’âs positive HIV status, and both partners are fully informed of the risks associated with 
IVF-âICSI and the risk of HIV transmission to the female partner and their potential offspring. Once an 
initial consultation has been performed and informed consent has been obtained, female patients may 
continue with the completion of the remaining screening requirements, which include the standard 
infertility evaluation (day-2 follicle-stimulating hormone and estradiol; screening for HIV, gonorrhea, 
chlamydia, syphilis, hepatitis B and hepatitis C; a pelvic ultrasound and sonohysterogram or 
hysterosalpingogram). Male seropositive partners must be currently under the care of an infectious 
disease specialist without any signs of AIDS or worsening infection. Prior to starting treatment, they 
must demonstrate stable HIV viral loads (250 cells/mm3 ) over a 6-month period. Standard infertility 
evaluation is also required, including blood screening for syphilis, hepatitis B and C; and a semen 
analysis to rule out possible male factor etiologies. Preferably, we advise men who are not currently 
on medication to begin HAART to reduce their viral loads prior to initiating therapy. 
Previous studies have demonstrated that males with chronic HIV infection often have abnormal semen 
analyses and hypogonadism [24,25] . From 1998 to 2007, our center found 42% of the male 
seropositive patients to have an abnormal semen analysis with at least one parameter in the subfertile 
range [26] . Although having a semen analysis with values in the subfertile range may initially seem 
inconsequential owing to our treatment with ICSI, males with severe oligospermia (abnormally low 
sperm counts) must have a semen analysis confirming at least 1 million total motile sperm in order to 
provide a sufficient amount for use following the sperm preparation process. This process can lead to 
a reduction in sperm count of up to 1 log in comparison to unprocessed ejaculate [12,27] . Owing to the 
theoretical risk of blood contamination of the sample, our male seropositive patients are not offered 
testicular sperm aspiration. While two case reports from European centers that offer microsurgical 
epididymal sperm aspiration to seropositive males with azoospermia (absence of sperm in the semen) 
were able to confirm negative testing of retrieved sperm samples prior to ICSI, the number of cases is 
minimal and only one pregnancy has resulted thus far [28,29] . 
For our male patients who meet the total motile sperm parameters, a fresh semen specimen is 
collected on the day of the oocyte retrieval. Semen preparation for ICSI involves a class II biologic 
hood using a modified density-gradient centrifugation and swim-up method to help remove 
nonspermatozoa cells infected with the virus [9,30] . Only the remaining motile spermatozoa found 
within the supernatant following this swim-up method are selected [31] . Currently available assays for 
detecting HIV-1 RNA or HIV-1 DNA in semen cells demonstrate false-positive rates of 18 and 19%, 
respectively, owing to the very low detection limits [32] . Unfortunately, this can lead to repeat semen 
collections, repeat testing and, ultimately, increased time and costs to patients. However, with real-
time PCR, collection and processing of semen samples can occur in 1 day, eliminating the need for 
cryopreservation [32] . At our center, selected spermatozoa do not undergo repeat testing for the virus 
prior to ICSI. Using the same semen processing technique as our center, Politch et al. reported 
exclusion of HIV-1 from the motile sperm fraction in ’âspiked’â semen samples using HIV-1 
concentrations exceeding those observed in individuals with advanced AIDS (1 million copies/ml) [33] . 
In this same study, HIV-1 was detected in some of the heavily concentrated samples (>1 billion 
copies/ml) and, for this reason, many centers advocate retesting samples prior to use [33] . One 
reproductive center in the UK performs repeat testing for detectable HIV RNA after sperm washing for 
IUI and IVF with ICSI [14] . This decision is based on the finding of 9.7% demonstrable virus found in 
pre- and post-wash IUI seminal samples of HIV-positive males undergoing HAART with undetectable 
viral loads at their center [14,22] . Although repeat testing occurs at many European centers, the 
majority of the current research has not demonstrated detectable HIV in the supernatant following 
modified density-gradient centrifugation and use of the swim-up method in individuals who meet our 
viral-load criteria [10,11,33] . Embryo transfers occur on day 3 (eight-cell stage of development), or day 
5/6 (blastocyst stage of development), in accordance with American Society for Reproductive Medicine 
(ASRM) guidelines. After their fresh embryo transfer, any remaining high-quality embryos can be 
cryopreserved for a future thawed embryo transfer if the couple desires [34] . 
After embryo transfer, it is important to follow-up with patients to ensure that the female partner and 
her fetus/infant remain uninfected. HIV DNA PCR and HIV RNA PCR are the post-treatment testing 
methods of choice owing to their high sensitivity. Female patients who do not become pregnant or 
have spontaneous abortions are tested 3 and 6 months after the embryo transfer. Pregnant patients 
are tested at each trimester, delivery and 3 months postpartum. Infants born to our serodiscordant 
couples are screened at birth and 3 months of age. Our procedures, to date, have not led to any 
female seroconversions or infected offspring, which is consistent with other published research 
utilizing IVF-âICSI procedures for serodiscordant couples [35-â42] . 
When is fertility treatment appropriate for discordant couples? Legal & ethical 
considerations  
Although it is now generally accepted that fertility treatment should not be withheld from HIV-
serodiscordant couples when appropriate treatment is available, this perspective has not always been 
endorsed, and this issue remains controversial [43] . More specifically, prior to the emergence of ARVs 
and before the extensive data on the safety of sperm preparation techniques to remove HIV were 
available, the Ethics Committee of the ASRM discouraged fertility treatment for serodiscordant couples 
using the HIV-infected male’âs sperm [44] . This stance was buttressed by a 1990 report by the CDC of 
a case in the USA involving improperly processed sperm that allegedly involved HIV transmission to a 
woman who was inseminated with her husband’âs sperm on three occasions in 1989, which did not 
result in a pregnancy [16] . In addition to concerns regarding possible transmission to the mother and 
child, the housing and processing of HIV-infected material creates a potential risk to staff as well as 
the uninfected gametes stored at a particular site [43] . 
However, the argument hinging on risk has been losing ground with the decreasing risk for 
transmission owing to the implementation of ARVs, effective semen processing and fertilization 
techniques, and greater knowledge among patients about preventing the spread of HIV. The empirical 
data overwhelmingly support the safety and efficacy of IVF-âICSI in order to minimize risk and 
increase success rates [19] . Legally, while donating HIV-positive semen is criminalized in some states, 
several states are catching up to the current ASRM guidelines and empirical evidence demonstrating 
that fertility treatment should not be denied to serodiscordant couples [45] . States in which donation of 
HIV-positive sperm is permitted generally stipulate that insemination may only occur when 
appropriate medical guidelines are followed and with detailed informed consent provided by the female 
partner who is the recipient of the sperm [45] . For example, the California Senate recently passed a 
bill that allows an exception to the law that prohibits the use of donated sperm that is HIV or human 
T-lymphotropic virus-1 positive in the event that the sperm will undergo advanced reproductive 
processing to reduce the risk of transmission, that the recipient receives prophylactic treatment to 
reduce risk of infection, and when both parties (sperm donor and recipient) provide informed consent 
[46] . 
A legal argument in favor of provision of fertility services for serodiscordant couples notes that failure 
to do so could be considered discriminatory. The Americans with Disabilities Act (ADA) prohibits 
discrimination against individuals with physical or mental disabilities to the extent that individuals who 
are HIV positive are considered to fall within this category; withholding fertility treatment for these 
individuals would be barred [103] . Furthermore, the Supreme Court case of Bragdon versus Abbott set 
the precedent that HIV-positive individuals cannot be discriminated against for healthcare-related 
services (in this case, a dental office) [47] . 
While the importance of protecting the rights of HIV-positive individuals is undeniable, others have 
raised the issue of the rights and welfare of the child being created through this process, in light of the 
possibility for premature paternal death [43] . However, the Ethics Committee of ASRM, has likened HIV 
in this context to autosomal recessive diseases, such as Tay-âSachs disease or cystic fibrosis, in that 
with appropriate testing and counseling, fully informed patients should have the right to choose to 
have their own biological children [48] . As such, this committee has argued that fertility services 
cannot be withheld on ethical grounds from individuals with chronic viral infections, including HIV, if a 
center has the resources to provide care. Moreover, the life expectancy of HIV-positive individuals has 
increased to more than 20 years after diagnosis, allowing HIV-positive fathers the opportunity to be 
fully involved in raising and caring for their children [1] . 
In 2004, prior to the statement from ASRM, the Ethics Task Force of the European Society of Human 
Reproduction and Embryology (ESHRE) also confirmed that assisted reproduction for HIV-positive 
people is ethically acceptable, as long as suitable precautions are taken. However, they also 
recommended against treatment for serodiscordant couples at that time [14] . The UK’âs regulatory 
body for ART clinics, The Code of Practice of the Human Fertilisation and Embryology Authority, 
released a statement in 2003 confirming HIV-positive patients’â rights to pursue treatment in order to 
have a child free of the virus [104] . Treatment centers in the UK, with the support of this regulatory 
body, are expected to offer reproductive and specialist HIV counseling for HIV-positive individuals [104] 
. Similar to the USA, few centers in the UK have pursued the necessary laboratory techniques required 
to provide treatment to HIV-positive patients pursuing reproductive assistance [14] . 
Future perspective  
Given the minimal risk of viral transmission and encouraging pregnancy rates, fertility treatment for 
HIV-serodiscordant couples is an important endeavor. We can expect that an increasing number of 
patients will be requiring such advanced reproductive techniques. As the need for these resources 
grows, we anticipate an increase in the number of centers offering these treatments in order to meet 
the demand and, as a function of the increased popularity of these techniques, we expect that 
screening will become more consistent across centers; this will allow for the simplification of 
treatment, referrals and consistency in research (e.g., facilitating meta-analytic studies). 
With that said, it is important to remember that patients have options and that treatment plans must 
be tailored to each specific couple’âs needs. Unfortunately, the areas of the world with the highest 
rates of HIV/AIDS, such as sub-Saharan Africa, are also the areas with the least access to treatment 
for HIV and reproductive options for HIV-serodiscordant couples who wish to conceive. In these 
regions, timed intercourse in the setting of optimal ARV might be the best option. 
In the USA, less than 3% of Society for ART-registered centers provide fertility treatment for HIV-
discordant (or HIV-concordant-positive) partners [34] . Given the rising number of serodiscordant 
couples, we can expect that an increasing number of patients will be requiring such advanced 
reproductive techniques and fertility centers will need to expand the scope of their practices. 
The future of the field of addressing the reproductive needs of the HIV population is extremely bright, 
and it is exciting to be able to offer multiple options to patients who were previously excluded from 
the reproductive community. 
Box 1. Screening requirements for HIV-serodiscordant couples pursuing assisted reproductive 
technology. 
Couple  
*âª Provide informed consent 
*âª Be practicing safe sexual intercourse (using condoms consistently) 
*âª Have a standard infertility evaluation 
*âª Undergo a normal physical examination (male and female) 
*âª Female partners must be seronegative 
*âª Be aware of partner’âs HIV status 
*âª Undergo HIV, gonorrhea, chlamydia, syphilis, hepatitis B and hepatitis C testing 
*âª Undergo pelvic examination (PAP smear and cervical cultures) 
*âª Be tested for serum estradiol and follicle-stimulating hormone concentrations 
*âª Undergo pelvic ultrasound 
*âª Undergo hysterosalpingogram 
Seropositive male partners  
*âª Be under active medical surveillance by an infectious disease specialist 
*âª Have plasma HIV RNA viral counts less than 50,000 copies/ml, stable over 6 months (preferably 
undetectable) 
*âª Have a CD4+ count of more than 250 cells/mm3 (preferably >400) 
*âª Have no evidence of AIDS or worsening infection 
*âª If not well controlled, taking highly active antiretroviral therapy 
*âª Undergo semen analysis with total motile sperm of at least 1 million 
*âª Undergo blood screening for syphilis, hepatitis B and hepatitis C 
Executive summary 
Fertility desires  
*âª With improved quality of life and life expectancy, largely owing to antiretroviral therapy for HIV, 
an increasing number of serodiscordant couples are interested in conceiving. 
*âª These couples can pursue many avenues to parenthood, from timed intercourse to using 
advanced reproductive technologies, which minimize the chance of possible horizontal or vertical HIV 
transmission. 
Timed intercourse  
*âª Timed intercourse is the least expensive alternative, although it exposes the female partner to the 
greatest risk of transmission, which is estimated to be approximately less than 1% per sexual 
encounter. 
Sperm preparation  
*âª Processed semen with ultracentrifugation steps and ’âswim-up’â is routinely performed prior to 
intrauterine insemination (IUI) or in vitro fertilization (IVF) with intracytoplasmic sperm injection 
(ICSI). 
Intrauterine insemination  
*âª IUI with prepared semen is associated with a lower financial cost and does not require oocyte 
retrieval or IVF. However, IUI is associated with a lower per-cycle success rate than IVF-âICSI, and 
there is an added exposure to the risk of infection with repetitive cycles. 
IVF-âICSI  
*âª For IVF with ICSI, the semen is processed and selected sperm are injected into the egg under 
direct visualization. 
Sperm characteristics  
*âª In those undergoing HAART therapy, semen samples are commonly abnormal, with semen 
volumes, percentages of progressive mobile spermatozoa, total sperm counts and polymorphonuclear 
cell counts being decreased, while pH values and spermatozoa multiple anomaly indices were 
increased. 
*âª HIV-1 viral DNA has been demonstrated in ejaculated abnormal spermatozoa in seropositive 
subjects. 
Columbia University HIV treatment paradigm  
*âª Our center has a standard procedure for working with serodiscordant patients, including screening 
and consultation of couples to ensure that the risk of transmission is minimized. 
*âª Male seropositive partners must be currently under the care of an infectious disease specialist 
without any signs of AIDS or worsening infection. 
*âª Procedures, to date, have not led to any female seroconversions or infected offspring. 
Legal ethical considerations  
*âª Concerns regarding risks of possible HIV transmission must be weighed against the rights of HIV-
positive individuals to have the same opportunity to conceive that others have. 
*âª Centers should consider the risk of transmission to the mother and child, as well as the fact that 
the storage and processing of HIV-infected material creates a potential risk to staff and the uninfected 
gametes stored at a particular site. 
Future perspective  
*âª There is an increasing need for advanced reproductive technologies for serodiscordant couples. 
While currently, less than 3% of Society for Assisted Reproductive Technologies-registered centers 
provide fertility treatment for HIV-discordant (or concordant-positive) partners, an increasing number 
of fertility centers are likely to offer HIV-specific treatment in the future in order to meet the 
increasing demand. 
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